-2.03%
Today
Loading 1D prices…
Company profile
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
7
Fiscal year end
1231
CIK
1566044
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| WHWKWhitehawk Therapeutics Inc. Common Stock | $217.2M | $7.1M | -288.26% | -$0.33 | -2.85% | Buy |
| RNACCartesian Therapeutics Inc. Common Stock | $224M | $400K | -32575.50% | -$5.02 | -2.62% | Buy |
| ELDNEledon Pharmaceuticals Inc. Common Stock | $214.1M | $0.00 | — | -$0.52 | -0.56% | Buy |
| NATRNature's Sunshine Products Inc. Common Stock | $226.5M | $480.1M | +4.07% | $1.06 | +0.08% | Buy |
| KROSKeros Therapeutics Inc. Common Stock | $226.6M | $244.1M | +35.65% | $2.30 | +0.69% | Buy |